GeneDx Holdings Corp.
NASDAQ:WGSMedical - Healthcare Information Services
+$1.52 today
- Market cap
- $1.56B
- Beta
- 1.97
- P/E (TTM)
- -21.8
- EPS (TTM)
- -$2.65
Volume 1.71M
Average 1.28M
WGS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
GeneDx Holdings Corp.NASDAQ: WGS
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2026 depreciation & amortization of $6.71M rose 8.4% year over year, behind the +15.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.4% from the prior quarter. Over 3 fiscal years it compounded at -24.8% a year.
Context
- Depreciation & amortization amounted to 5.9% of revenue in FY2025, down 1.3 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +8.4% toward the trailing-twelve-month pace of +15.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 25.22M USD
- Year-over-year change
- +14.9%
- 4-year CAGR
- +3.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.22M | +14.9% |
| FY2024 | 2024-12-31 | 21.95M | -34.9% |
| FY2023 | 2023-12-31 | 33.73M | -43.1% |
| FY2022 | 2022-12-31 | 59.31M | +172.0% |
| FY2021 | 2021-12-31 | 21.81M | — |
Depreciation & Amortization vs competitors
How WGS compares with its peers on the latest reported figures
- WGS's LTM Jun 2026 depreciation & amortization of $26.88M is the 3rd largest of the 9 companies compared; the peer median is $13.62M.
- Its year-over-year change of +15.1% is the 2nd highest of 8, against a peer median of -8.0%.
- Depreciation & amortization amounts to 5.9% of revenue for WGS, versus a peer median of 8.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $65.46M | -8.0% | -0.8% | 8.5% | |
| LTM Mar 2026 | $51.8M | -13.5% | +0.6% | 6.2% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $26.88M | +15.1% | -24.8% | 5.9% |
| LTM Mar 2026 | $24.2M | +0.1% | -9.6% | 7.6% | |
| LTM Mar 2026 | $14.94M | -64.8% | +57.0% | 4.4% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $12.3M | — | — | 3.1% |
| LTM Mar 2026 | $9.83M | -8.1% | +6.0% | 15.2% | |
| FY2025 | $9.21M | +14.5% | +23.3% | 8.5% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $2.34M | +35.9% | -25.1% | 119.9% |
| Peer median (excluding WGS) | $13.62M | -8.0% | +0.6% | 8.0% | |
Competitors are the stored peer set for WGS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (245.39M) | (548.98M) | (175.77M) | (52.29M) | (21.02M) |
| Depreciation & Amortization | 21.81M | 59.31M | 33.73M | 21.95M | 25.22M |
| Deferred Income Tax | 0 | (49.12M) | (926K) | (343K) | 0 |
| Stock-Based Compensation | 219.42M | 41.98M | (326K) | 9.14M | 32.16M |
| Change in Working Capital | 8.08M | 36.13M | (38.24M) | (24.75M) | (15.6M) |
| Accounts Receivables | 5.54M | 5.53M | 10.26M | (5.42M) | (36.23M) |
| Inventory | (10.62M) | 4.6M | 975K | (2.59M) | (3.44M) |
| Accounts Payables | 0 | 34.46M | (46.95M) | (20.46M) | 12.1M |
| Other Working Capital | 13.17M | (8.46M) | (2.53M) | 3.72M | 11.97M |
| Other Non-Cash Items | (194.35M) | 141.53M | 1.38M | 17.79M | 12.51M |
| Operating Cash Flow | (190.43M) | (319.16M) | (180.15M) | (28.5M) | 33.28M |
| Capital Expenditures | (20.79M) | (14.32M) | (5.71M) | (5.49M) | (19.02M) |
| Acquisitions (Net) | 0 | (127M) | (8.11M) | 0 | (32.86M) |
| Purchases of Investments | 0 | 0 | (47.67M) | (66.3M) | (55.68M) |
| Sales of Investments | 0 | 0 | 17.77M | 41.66M | 46.03M |
| Other Investing Activities | (11.39M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (20.79M) | (141.33M) | (43.73M) | (30.13M) | (61.52M) |
| Debt Repayment | (13.47M) | (3.29M) | 42.95M | (3.23M) | (3.66M) |
| Common Stock Issued | 442.68M | 197.66M | 143M | 46.5M | 51.69M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 64.51M | 2.95M | 285K | 891K | 0 |
| Financing Cash Flow | 493.73M | 197.32M | 186.24M | 44.16M | 48.03M |
| Effect of Forex Changes | 0 | 0 | (87K) | 0 | 0 |
| Net Change in Cash | 282.51M | (263.17M) | (37.72M) | (14.47M) | 19.79M |
| Free Cash Flow | (211.22M) | (333.48M) | (185.86M) | (33.99M) | 14.26M |
GeneDx Holdings Corp.
NASDAQ:WGS
Intrinsic Alpha fair value
Locked
Current Price
$51.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.